These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 35707828)
1. The sodium-glucose co-transporter 2 inhibitor tofogliflozin suppresses atherosclerosis through glucose lowering in ApoE-deficient mice with streptozotocin-induced diabetes. Iwamoto M; Kubota T; Sakurai Y; Wada N; Shioda S; Yamauchi T; Kadowaki T; Kubota N Pharmacol Res Perspect; 2022 Aug; 10(4):e00971. PubMed ID: 35707828 [TBL] [Abstract][Full Text] [Related]
2. Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice. Nagata T; Fukuzawa T; Takeda M; Fukazawa M; Mori T; Nihei T; Honda K; Suzuki Y; Kawabe Y Br J Pharmacol; 2013 Oct; 170(3):519-31. PubMed ID: 23751087 [TBL] [Abstract][Full Text] [Related]
3. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. Suzuki M; Honda K; Fukazawa M; Ozawa K; Hagita H; Kawai T; Takeda M; Yata T; Kawai M; Fukuzawa T; Kobayashi T; Sato T; Kawabe Y; Ikeda S J Pharmacol Exp Ther; 2012 Jun; 341(3):692-701. PubMed ID: 22410641 [TBL] [Abstract][Full Text] [Related]
4. The sodium-glucose cotransporter 2 inhibitor tofogliflozin prevents diabetic kidney disease progression in type 2 diabetic mice. Li Z; Murakoshi M; Ichikawa S; Koshida T; Adachi E; Suzuki C; Ueda S; Gohda T; Suzuki Y FEBS Open Bio; 2020 Dec; 10(12):2761-2770. PubMed ID: 33098615 [TBL] [Abstract][Full Text] [Related]
5. The Effect of Sodium-Dependent Glucose Cotransporter 2 Inhibitor Tofogliflozin on Neurovascular Coupling in the Retina in Type 2 Diabetic Mice. Hanaguri J; Yokota H; Kushiyama A; Kushiyama S; Watanabe M; Yamagami S; Nagaoka T Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163285 [TBL] [Abstract][Full Text] [Related]
6. Amelioration of Hyperglycemia with a Sodium-Glucose Cotransporter 2 Inhibitor Prevents Macrophage-Driven Atherosclerosis through Macrophage Foam Cell Formation Suppression in Type 1 and Type 2 Diabetic Mice. Terasaki M; Hiromura M; Mori Y; Kohashi K; Nagashima M; Kushima H; Watanabe T; Hirano T PLoS One; 2015; 10(11):e0143396. PubMed ID: 26606676 [TBL] [Abstract][Full Text] [Related]
7. The SGLT-2 Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE Leng W; Ouyang X; Lei X; Wu M; Chen L; Wu Q; Deng W; Liang Z Mediators Inflamm; 2016; 2016():6305735. PubMed ID: 28104929 [No Abstract] [Full Text] [Related]
8. The effect of sodium-glucose cotransporter 2 inhibitor (tofogliflozin) on renal tubular damage in diabetic patients without albuminuria. Shimohata H; Iwaki Y; Yamashita M; Ohgi K; Maruyama H; Takayasu M; Hirayama K; Kobayashi M Int Urol Nephrol; 2022 Aug; 54(8):1907-1914. PubMed ID: 34843041 [TBL] [Abstract][Full Text] [Related]
9. Tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, suppresses renal damage in KKAy/Ta mice, obese and type 2 diabetic animals. Ishibashi Y; Matsui T; Yamagishi SI Diab Vasc Dis Res; 2016 Nov; 13(6):438-441. PubMed ID: 27407083 [TBL] [Abstract][Full Text] [Related]
10. The SGLT2 Inhibitor Luseogliflozin Rapidly Normalizes Aortic mRNA Levels of Inflammation-Related but Not Lipid-Metabolism-Related Genes and Suppresses Atherosclerosis in Diabetic ApoE KO Mice. Nakatsu Y; Kokubo H; Bumdelger B; Yoshizumi M; Yamamotoya T; Matsunaga Y; Ueda K; Inoue Y; Inoue MK; Fujishiro M; Kushiyama A; Ono H; Sakoda H; Asano T Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28777298 [TBL] [Abstract][Full Text] [Related]
11. Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice. Ganbaatar B; Fukuda D; Shinohara M; Yagi S; Kusunose K; Yamada H; Soeki T; Hirata KI; Sata M Eur J Pharmacol; 2020 May; 875():173040. PubMed ID: 32114052 [TBL] [Abstract][Full Text] [Related]
12. Central administration of sodium-glucose cotransporter-2 inhibitors increases food intake involving adenosine monophosphate-activated protein kinase phosphorylation in the lateral hypothalamus in healthy rats. Takeda K; Ono H; Ishikawa K; Ohno T; Kumagai J; Ochiai H; Matumoto A; Yokoh H; Maezawa Y; Yokote K BMJ Open Diabetes Res Care; 2021 Apr; 9(1):. PubMed ID: 33879516 [TBL] [Abstract][Full Text] [Related]
13. Effect of Tofogliflozin on Systolic and Diastolic Cardiac Function in Type 2 Diabetic Patients. Otagaki M; Matsumura K; Kin H; Fujii K; Shibutani H; Matsumoto H; Takahashi H; Park H; Yamamoto Y; Sugiura T; Shiojima I Cardiovasc Drugs Ther; 2019 Aug; 33(4):435-442. PubMed ID: 31321581 [TBL] [Abstract][Full Text] [Related]
14. Switching Dipeptidyl Peptidase-4 Inhibitors to Tofogliflozin, a Selective Inhibitor of Sodium-Glucose Cotransporter 2 Improve Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index in Patients with Type 2 Diabetes: A Pilot Study. Bekki M; Tahara N; Tahara A; Igata S; Honda A; Sugiyama Y; Nakamura T; Sun J; Kumashiro Y; Matsui T; Fukumoto Y; Yamagishi SI Curr Vasc Pharmacol; 2019; 17(4):411-420. PubMed ID: 29766812 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of the effect of tofogliflozin on the tissue characteristics of the carotid wall-a sub-analysis of the UTOPIA trial. Katakami N; Mita T; Maeda N; Sato Y; Watada H; Shimomura I; Cardiovasc Diabetol; 2022 Feb; 21(1):19. PubMed ID: 35123483 [TBL] [Abstract][Full Text] [Related]
19. Dapagliflozin Does Not Modulate Atherosclerosis in Mice with Insulin Resistance. Taberner-Cortés A; Vinué Á; Herrero-Cervera A; Aguilar-Ballester M; Real JT; Burks DJ; Martínez-Hervás S; González-Navarro H Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33287201 [TBL] [Abstract][Full Text] [Related]
20. Suppressive effects of the sodium‑glucose cotransporter 2 inhibitor tofogliflozin on colorectal tumorigenesis in diabetic and obese mice. Kato J; Shirakami Y; Ohnishi M; Mizutani T; Kubota M; Sakai H; Ibuka T; Tanaka T; Shimizu M Oncol Rep; 2019 Dec; 42(6):2797-2805. PubMed ID: 31638239 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]